Press Releases



MORGANTOWN, W. Va., June 30, 2022 -- Protea Biosciences, Inc., a leader in the development of new protein separations technology, today announced the launch of new protein identification services for the Biotechnology and Pharmaceutical Research Industry.

The new services offer improved capability to identify proteins in complex mixtures, and generate protein databases, including the full-scale analysis of protein samples, and the generation of protein databases, organized and retrievable in user-friendly formats.

Protea’s services utilize new, proprietary protein separation technology that improves on the current state-of-the-art.

“We utilize the very latest instrumentation, which, when combined with our own protein separation technology, allows us to generate the highest quality protein identification data -- rapidly, and reproducibly,” stated Matthew Powell, Ph.D., manager of Protea’s Protein Research Laboratory.  “Our laboratory focuses on developing more robust techniques for protein characterization and identification, and offers these to the Biotechnology and Pharmaceutical industry.”

“We focus on Biopharmaceutical companies who need reproducible data with rapid turnaround, for the identification of proteins in complex mixtures.  This is a major challenge for companies engaged in protein-based, pharmaceutical development,” commented Steve Turner, Protea’s Chief Executive Officer.  “Our goal is to advance the state-of-the-art, to provide rapid and reproducible protein identification capability to support their development programs.”

Protea Biosciences, Inc. ( develops new technologies for improved protein separation and identification, and provides products and services for protein identification to the pharmaceutical, biotechnology and academic research community.


Protea To Provide Proteomics Services to Novartis Pharmaceuticals Corporation
January 8, 2022

Morgantown, West Virginia - Protea Biosciences, Inc., West Virginia’s first Biotechnology company, announced today that it has entered into a contract to provide Proteomics Services to Novartis Pharmaceuticals Corporation. The company will be applying its Proteomics technology to the identification of new protein "Biomarkers" present in the blood samples of Cancer patients.

"We are pleased to be collaborating with Novartis", commented Steve Turner, Protea’s President, "They are leaders in Cancer Research, and have a long history as innovators in the field. Working together, we will seek to identify new protein biomarkers, that will support the design of improved drug therapies for cancer patients."

Under terms of the contract, Protea scientists will use a new technology, known as "Solution-based ultrasensitive Mass Spectrometry", to analyze and identify proteins secreted by the individual cells of cancer patients. The collaboration is focused on identifying protein biomarkers present in human sera that will allow physicians to identify specific cancers earlier, predict their aggressiveness, and design new treatments.

Protea’s mission is to create a leading Proteomics business by developing and commercializing West Virginia University – based Proteomics technology and applying it to the discovery of new, disease-specific protein targets, for use in the development of new pharmaceuticals and biomarkers for the improved management of Cancer and other human disease.